Loading Events

Reviva Pharmaceuticals KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

DATE: February 15, 2024
TIME: 12:00 PM EST

About The Event

Join Reviva Pharmaceuticals for a virtual key opinion leader (KOL) event, featuring Larry Ereshefsky, PharmD, BCPP, FCCP (Retired professor of Psychiatry, Pharmacology and Psychiatry, The University of Texas; Chief Scientific Officer, Owner, Follow the Molecule LLC) and Mark Opler, PhD, MPH (Chief Research Officer at WCG Inc., Executive Director of the PANSS Institute), who will discuss the unmet medical need and current treatment landscape for patients suffering from acute to chronic symptoms of schizophrenia, and brilaroxazine (RP5063), a next-generation serotonin/ dopamine modulator, as a potential treatment.

The event will focus on reviewing Reviva’s positive topline results and successful completion of pivotal Phase 3 RECOVER trial evaluating the efficacy, safety, and tolerability of once-daily brilaroxazine in adults with acute schizophrenia, as well as the Company’s ongoing enrollment in the one-year open label extension (OLE) trial and the initiation of registrational Phase 3 RECOVER-2 trial.

A live question and answer session will follow the formal presentations.